

In the specification:

Please amend the portion of the specification beginning at page 19, line 5, and continuing to the first line of page 21 as follows:

(*E,E*)-2-(benzylaminocarbonyl~~de~~)-3-styrylacrylonitrile (CR1);  
(*E,E*)-2-(benzylaminocarbonyl~~de~~)-3-(3,4-dimethoxystyryl)acrylonitrile (CR2);  
(*E,E*)-2-(benzylaminocarbonyl~~de~~)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR3);  
(*E,E*)-2-(benzylaminocarbonyl~~de~~)-3-(3,4-dihydroxystyryl)acrylonitrile (CR4);  
(*E,E*)-2-(phenylethylaminocarbonyl~~de~~)-3-(3,4-dimethoxystyryl)acrylonitrile (CR5);  
(*E,E*)-2-(phenylethylaminocarbonyl~~de~~)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR8);  
(*E,E*)-2-(phenylpropylaminocarbonyl~~de~~)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR9);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl~~de~~)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR11);  
(*E,E*)-2-aminothiocabonyl~~thioacetamido~~-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR12);  
(*E,E*)-2-aminocarbonyl~~acetamido~~-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR13);  
(*E,E*)-2-carboxy-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR14);  
(*E,E*)-2-carbomethoxy-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR15);  
(*E,E*)-2-aminocarbonyl~~acetamido~~-3-[3,4-bis(t-butyldimethylsilyloxy)styryl]]acrylonitrile (CR16);  
(*E,E*)-2-aminocarbonyl~~acetamido~~-3-(3,4-dihydroxystyryl)acrylonitrile (CR17);  
(*E,E*)-2-(benzylaminocarbonyl~~de~~)-3-[[3,4-bis(t-butyldimethylsilyloxy)styryl]]acrylonitrile (CR18);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl~~de~~)-3-styrylacrylonitrile (CR19);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl~~de~~)-3-[3,4-bis(t-butyldimethylsilyloxy)styryl]]acrylonitrile (CR20);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl~~de~~)-3-(3,4-dihydroxystyryl)acrylonitrile (CR21);

(*E,E*)-2-( $\beta$ -ethanolaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR24);  
 (*E,E*)-2-(benzylaminocarbonyl)-3-(4-nitrostyryl)acrylonitrile (CR27);  
 (*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(4-nitrostyryl)acrylonitrile (CR28); and  
 (*ZE,E*)-2-(1-amino-2,2-dicyanoethenyl)-3-(4-nitrostyryl)acrylonitrile (CR29).

In preferred embodiments of the present invention, the compounds of the invention include:

(*E,E*)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (CR1);  
 (*E,E*)-2-(benzylaminocarbonyl)-3-(3,4-dimethoxystyryl)acrylonitrile (CR2);  
 (*E,E*)-2-(benzylaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR3);  
 (*E,E*)-2-(benzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylonitrile (CR4);  
 (*E,E*)-2-(phenylethylaminocarbonyl)-3-(3,4-dimethoxystyryl)acrylonitrile (CR5);  
 (*E,E*)-2-(phenylpropylaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR9);  
 (*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR11);  
 (*E,E*)-2-aminothiocabonylthioacetamide-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR12);  
 (*E,E*)-2-aminocabonylacetamide-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR13);  
 (*E,E*)-2-carboxy-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR14);  
 (*E,E*)-2-carbomethoxy-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR15);  
 (*E,E*)-2-aminocabonylacetamide-3-(3,4-dihydroxystyryl)acrylonitrile (CR17);  
 (*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-styrylacrylonitrile (CR19);  
 (*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylonitrile (CR21); and  
 (*E,E*)-2-( $\beta$ -ethanolaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR24).

In more preferred embodiments of the present invention, the compounds of the invention include:

(*E,E*)-2-(benzylaminocarbonylde)-3-(3,4-dihydroxystyryl)acrylonitrile (CR4);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonylde)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR11);  
(*E,E*)-2-aminocarbonylaacetamide-3-(3,4-dihydroxystyryl)acrylonitrile (CR17);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonylde)-3-styrylacrylonitrile (CR19);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonylde)-3-(3,4-dihydroxystyryl)acrylonitrile (CR21); and  
(*E,E*)-2-( $\beta$ -ethanolaminocarbonylde)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile

Please amend the section of the specification from page 26, line 8, to page 27, line 16, as follows:

(*E,E*)-2-(benzylaminocarbonylde)-3-styrylacrylonitrile (CR1);  
(*E,E*)-2-(benzylaminocarbonylde)-3-(3,4-dimethoxystyryl)acrylonitrile (CR2);  
(*E,E*)-2-(benzylaminocarbonylde)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR3);  
(*E,E*)-2-(benzylaminocarbonylde)-3-(3,4-dihydroxystyryl)acrylonitrile (CR4);  
(*E,E*)-2-(phenylethylaminocarbonylde)-3-(3,4-dimethoxystyryl)acrylonitrile (CR5);  
(*E,E*)-2-(phenylethylaminocarbonylde)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR8);  
(*E,E*)-2-(phenylpropylaminocarbonylde)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR9);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR11);  
(*E,E*)-2-aminothiocarbonylthioacetamide-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR12);

*(E,E)*-2-aminocarbonylacetamide-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR13);  
*(E,E)*-2-carboxy-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR14);  
*(E,E)*-2-carbomethoxy-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR15);  
*(E,E)*-2-aminocarbonylacetamide-3-[3,4-bis(*t*-butyldimethylsilyloxy)styryl]]acrylonitrile (CR16);  
*(E,E)*-2-aminocarbonylacetamide-3-(3,4-dihydroxystyryl)acrylonitrile (CR17);  
*(E,E)*-2-(benzylaminocarbonyl~~ide~~)-3-[[3,4-bis(*t*-butyldimethylsilyloxy)styryl]]acrylonitrile (CR18);  
*(E,E)*-2-(3,4-dihydroxybenzylaminocarbonyl~~ide~~)-3-styrylacrylonitrile (CR19);  
*(E,E)*-2-(3,4-dihydroxybenzylaminocarbonyl~~ide~~)-3-[3,4-bis(*t*-butyldimethylsilyloxy)styryl]]acrylonitrile (CR20);  
*(E,E)*-2-(3,4-dihydroxybenzylaminocarbonyl~~ide~~)-3-(3,4-dihydroxystyryl)acrylonitrile (CR21);  
*(E,E)*-2-(β-ethanolaminocarbonyl~~ide~~)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR24);  
*(E,E)*-2-(benzylaminocarbonyl~~ide~~)-3-(4-nitrostyryl)acrylonitrile (CR27);  
*(E,E)*-2-(3,4-dihydroxybenzylaminocarbonyl~~ide~~)-3-(4-nitrostyryl)acrylonitrile (CR28); and  
*(Z,E)*-2-(1-amino-2,2-dicyanoethenyl)-3-(4-nitrostyryl)acrylonitrile (CR29).

In a preferred embodiment, the present invention provides a method of inhibiting the proliferation of a cancer cell comprising administering an effective amount of a compound selected from the group of compounds:

*(E,E)*-2-(benzylaminocarbonyl~~ide~~)-3-(3,4-dihydroxystyryl)acrylonitrile (CR4);  
*(E,E)*-2-(3,4-dihydroxybenzylaminocarbonyl~~ide~~)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR11);  
*(E,E)*-2-aminocarbonylacetamide-3-(3,4-dihydroxystyryl)acrylonitrile (CR17);  
*(E,E)*-2-(3,4-dihydroxybenzylaminocarbonyl~~ide~~)-3-styrylacrylonitrile (CR19);  
*(E,E)*-2-(3,4-dihydroxybenzylaminocarbonyl~~ide~~)-3-(3,4-dihydroxystyryl)acrylonitrile (CR21); and

(E,E)-2-( $\beta$ -ethanolaminocarbonyl~~de~~)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile

Please amend the last paragraph on page 35 as follows:

**Example 3: (E,E)-2-(3,4-Dihydroxybenzylaminocarbonyl~~de~~)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR11)**

Please amend line 6 on page 38 as follows:

**Example 7: (E,E)-2-(Benzylaminocarbonyl~~de~~)-3-(3,4-dimethoxystyryl)acrylonitrile**

Please amend line 20 on page 38 as follows:

**Example 8: (E,E)-2-(Benzylaminocarbonyl~~de~~)-3-(3,4-dihydroxystyryl)acrylonitrile**

Please amend the last paragraph on page 40 as follows:

**Example 12: (E,E)-2-(Benzylaminocarbonyl~~de~~)-3-([3,4-bis(t-Butyldimethylsilyloxy)styryl])acrylonitrile (CR18)**

Please amend line 16 on page 41 as follows:

**Example 13: (E,E)-2-(Benzylaminocarbonyl~~de~~)-3-(3,4-dihydroxystyryl)acrylonitrile**

Please amend line 1 on page 42 as follows:

**Example 14: (E,E)-2-(3,4-Dihydroxybenzylaminocarbonyl)-3-styrylacrylonitrile**

Please amend lines 16-17 on page 42 as follows:

**Example 15: (E,E)-2-(3,4-Dihydroxybenzylaminocarbonyl)-3-[3,4-bis(t-butylidimethylsilyloxy)styryl]acrylonitrile (CR20)**

Please amend lines 6-7 on page 43 as follows:

**Example 16: (E,E)-2-(3,4-Dihydroxybenzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylonitrile (CR21)**

Please amend line 21 on page 43 as follows:

**Example 17: (E,E)-2-(Benzylaminocarbonyl)-3-styrylacrylonitrile (CR1)**

Please amend lines 7-8 on page 44 as follows:

**Example 18: (E,E)-2-(Benzylaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR3)**

Please amend lines 21-22 on page 45 as follows:

**Example 21: (E,E)-2-(Phenylethylaminocarbonyl)-3-(3,4-dimethoxystyryl)acrylonitrile (CR5)**

Please amend lines 11-12 on page 46 as follows:

**Example 22: (E,E)-2-(Phenyl thylaminocarbonyl~~de~~)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR8)**

Please amend the last paragraph on page 46 as follows:

**Example 23: (E,E)-2-(Phenylpropylaminocarbonyl~~de~~)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR9)**

Please amend lines 16-17 of page 47 as follows:

**Example 24: (E,E)-2- Aminothiocabonyl~~Thioacetamido~~ -3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR12)**

Please amend lines 5-6 of page 48 as follows:

**Example 25: (E,E)-2-Aminocarbonyl~~Acetamido~~-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR13)**

Please amend lines 21-22 of page 49 as follows:

**Example 28: (E,E)-2-Aminocarbonyl~~Acetamido~~-3-[3,4-bis(t-Butyldimethylsilyloxy)styryl]]acrylonitrile\_(CR16)**

Please amend line 9 of page 50 as follows:

**Example 29: (E,E)-2-Aminocarbonyl~~Acetamido~~-3-(3,4-dihydroxystyryl)acrylonitrile**

Please amend the first paragraph of page 51 as follows:

**Exempl 31: (E,E)-2-( $\beta$ -Ethanolaminocarbonyl~~de~~)-3-(3,5-dim thoxy-4-hydroxystyryl)acrylonitrile (CR24)**

Please amend line 15 of page 51 as follows:

**Example 32: (E,E)-2-(Benzylaminocarbonyl~~de~~)-3-(4-nitrostyryl)acrylonitrile (CR27)**

Please amend the first full paragraph on page 52 as follows:

**Example 33: (E,E)-2-(3,4-Dihydroxybenzylaminocarbonyl~~de~~)-3-(4-nitrostyryl)acrylonitrile (CR28)**

Please amend lines 21-22 of page 52 as follows:

**Example 34: (ZE,E)-2-(1-Amino-2,2-dicyanoethenyl)-3-(4-nitrostyryl)acrylonitrile (CR29)**